4//SEC Filing
Feingold Jay 4
Accession 0001209191-23-021412
CIK 0001782223other
Filed
Mar 27, 8:00 PM ET
Accepted
Mar 28, 4:45 PM ET
Size
14.9 KB
Accession
0001209191-23-021412
Insider Transaction Report
Form 4
Feingold Jay
Chief Medical Officer
Transactions
- Award
Stock Option (Right to buy)
2023-03-24+17,517→ 17,517 totalExercise: $2.21Exp: 2031-09-14→ Common Stock (17,517 underlying) - Disposition to Issuer
Stock Option (Right to buy)
2023-03-24−157,257→ 0 totalExercise: $8.71Exp: 2031-09-12→ Common Stock (157,257 underlying) - Award
Common Stock
2023-03-24+209,803→ 730,345 total - Award
Stock Option (Right to buy)
2023-03-24+157,257→ 157,257 totalExercise: $2.21Exp: 2031-09-12→ Common Stock (157,257 underlying) - Disposition to Issuer
Stock Option (Right to buy)
2023-03-24−17,517→ 0 totalExercise: $8.71Exp: 2031-09-14→ Common Stock (17,517 underlying)
Footnotes (4)
- [F1]Represents restricted stock units that vest 25% on March 24, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
- [F2]In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.
- [F3]These stock options vested 25% on the first anniversary of the September 13, 2021 grant date, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
- [F4]These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
Documents
Issuer
Pyxis Oncology, Inc.
CIK 0001782223
Entity typeother
Related Parties
1- filerCIK 0001885838
Filing Metadata
- Form type
- 4
- Filed
- Mar 27, 8:00 PM ET
- Accepted
- Mar 28, 4:45 PM ET
- Size
- 14.9 KB